Chemotherapy-Induced Peripheral Neuropathy
Online Cognitive Behavioral Therapy May Provide Pain Relief in Chemotherapy-Induced Peripheral NeuropathyJanuary 18, 2018
Self-guided online cognitive behavioral pain management may result in improved "worst" pain but not "average" pain compared with usual care for the treatment of painful chemotherapy-induced peripheral neuropathy.
A recent study evaluated the efficacy of cryotherapy for chemo-induced peripheral neuropathy; study participants wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion.
The researchers found that paclitaxel triggers CIPN by altering IP3 receptor phosphorylation and intracellular calcium flux and activating calcium-dependent calpain proteases.
Multivitamin use before diagnosis of breast cancer is associated with reduced risk of symptoms of chemotherapy-induced peripheral neuropathy.
Patients in the neurofeedback group reported significant declines in CIPN symptoms, compared with patients who did not get neurofeedback training.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness